Search for a trial

Concomitant intraperitoneal and systemic chemotherapy in patients with extensive peritoneal carcinomatosis of colorectal origin

Main objective of this project is to establish the maximum tolerable dose (MTD) and recommended phase II dose of intraperitoneal irinotecan in patients with PC of colorectal origin, added to standard of care systemic chemotherapy. Other endpoints…

Concomitant intraperitoneal and systemic chemotherapy in patients with extensive peritoneal carcinomatosis of gastric origin

This study has been transitioned to CTIS with ID 2024-516265-37-00 check the CTIS register for the current data. The primary goal of the study is to establish the maximum tolerated dose (MTD) of intraperitoneal administration of irinotecan, added to…

Perioperative systemic therapy and cytoreductive surgery with HIPEC versus upfront cytoreductive surgery with HIPEC alone: a multicentre, open-label, parallel-group, phase II-III, randomised superiority study (CAIRO6).

This study has been transitioned to CTIS with ID 2024-518570-13-00 check the CTIS register for the current data. Objectives of the phase II study (80 patients) are to explore the feasibility of accrual, the feasibility, safety, and tolerance of…

Intraperitoneal irinotecan with concomitant FOLFOX and bevacizumab for patients with unresectable colorectal peritoneal metastases - a phase II study

This study has been transitioned to CTIS with ID 2024-517152-34-00 check the CTIS register for the current data. The primary objectives are to explore the overall survival for the addition of intraperitoneal irinotecan (75 mg) to palliative systemic…